Navigation Links
ThermoGenesis Announces National Institute of Health Grant
Date:6/9/2009

COMPANY'S FIRST-EVER NIH GRANT WILL BE USED TO DEVELOP CELL DELIVERY TECHNOLOGIES FOR REGENERATIVE MEDICINE APPLICATIONS

RANCHO CORDOVA, Calif., June 9 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today it has received a grant from the National Institute of Health (NIH) to study and develop biomaterials that can be used to deploy placental stem cells in bone repair and regenerative medicine applications.

The approximate $500,000, two-year grant, the Company's first-ever funding from the NIH, is a Phase I Small Business Innovation Research grant from the National Institute on Aging. The study will be conducted at the Company's stem cell research laboratory and through a collaboration with the University of California, Davis. The Company can apply for a Phase II grant once the work under this initial contract is completed.

"Being awarded this grant is an important milestone for the Company. These funds enable us to conduct exploratory research in animal models to identify the best methods of combining stem cells with biomaterials," noted Mel Engle, Chief Executive Officer of ThermoGenesis. "We will be using stem cell concentrates prepared by our AXP(TM) AutoXpress (AXP(TM)), MarrowXpress(TM) (MXP) and Res-Q(TM) cell separation technologies as well as cells derived from the placenta. The goal of this research is to provide an integrated cell processing and delivery system designed to achieve an optimal therapeutic effect in orthopedic applications, such as bone repair and generation." Engle said the Company's research is based upon the growing body of evidence which shows that the efficacy of stem cells for tissue regeneration and repair can be enhanced if the cells are presented to the body within bioengineered materials.

The AXP is used for the processing of stem cells from umbilical cord blood, while the Res-Q a point-of-care device scheduled for launch later this month and the MXP are used to prepare cell concentrates from bone marrow. The Res-Q Platform is also being studied for potential use in the preparation of platelet rich plasma (PRP) from peripheral blood.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

  • The BioArchive(R) System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP(TM) AutoXpress Platform (AXP(TM)), a proprietary family of automated devices that includes the AXP and the MarrowXpress and companion sterile blood processing disposable for harvesting stem cells in a closed system. The AXP device is used for the processing of umbilical cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product, except Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors.
  • MarrowXpress, a device used for isolating stem cells from bone marrow.
  • The Res-Q(TM), a point-of-care system designed for bone marrow stem cell processing for the human market. It is anticipated that this offering will be available in June 2009.
  • The CryoSeal(R) FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new product scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

                                  ThermoGenesis Corp.
                        Web site:http://www.thermogenesis.com
                             Contact: Investor Relations
                                  +1-916-858-5107, or
                                  ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Sanovas, Inc., a life science asset holding company ... wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed Intubation ... http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed annually ...
(Date:12/5/2016)... Health and Gateway Health proudly announce a dynamic collaboration that ... plan members with specific high risk needs. In ... group of consumers, Wellbridge combines technology and population expertise with ... members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... Dec. 5, 2016  Recently Zymo Research announced ... predictor, known as Horvath,s Clock. Based on this ... analysis service to academic and biopharma scientific researchers ... sample, other than sperm. The service ... biological age versus chronological age following drug treatments ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 06, 2016 , ... Specialty Technical Publishers (STP) and Specialty ... Consortium (IAPC) EHS audit protocol for Great Britain . Leading companies around ... EHS regulatory obligations and rapidly collect, share, archive, and export audit findings in ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... to "Training" magazine’s 2017 Training Top 125 for their industry leading training methods ... annual award recognizes USA as among the global elite in employer-sponsored training and ...
(Date:12/5/2016)... ... December 05, 2016 , ... The ... care facility – Avamere Transitional Care of Puget Sound ; located at ... health care center will provide patients recovering from illness or injury with intensive ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All Children’s Hospital want ... athletes. Over the course of three years, researchers will study concussions and changes in ... guards, equipped with special sensors, will track the location and force of the hit. ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... Keynote speaker for the 21st Annual International Congress on Hematologic Malignancies®: Focus on ... PER® president, Phil Talamo said, “We are honored to have Amy E. Herman ...
Breaking Medicine News(10 mins):